(Nasdaq: ONCY) Could Disrupt A Potential $30Bn Market (5 Potential Catalysts On Watch)

Breakthroughs in cancer treatment are picking up speed.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: ONCY) Could Disrupt A Potential $30Bn Market (5 Potential Catalysts On Watch) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* June 1st Greetings, Friend! Breakthroughs in cancer treatment are picking up speed. Why? They're being driven by growing demand for therapies that work more effectively. Within this landscape, the gastrointestinal cancer segment is seeing notable expansion, increasing from $27.05Bn in 2025 to $30.33Bn in 2026. Still flying under-the-radar at this moment, one clinical-stage biotech firm has begun to draw attention for its distinct strategy. The strategy centers on immune-based approaches to address tumors that have proven difficult to treat. Rather than broadly targeting cells, its work emphasizes precision, aiming to attack cancer while leaving healthy tissue largely unaffected, placing it squarely in an area where treatment options remain limited. This momentum highlights a larger transformation underway in how cancer treatment could evolve in the coming years. And with an average analyst target pointing to the potential for triple-digit upside, this Nasdaq profile is now on our radar: Oncolytics Biotech Inc. (Nasdaq: ONCY). Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent.  Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. Pelareorep is a first-in-class, nonpathogenic, oncolytic virus that can be delivered intravenously and works by generating, recruiting, and training immune cells to recognize and kill cancer while remodeling the tumor microenvironment to enable immune cell access.  In addition to its demonstrated single-agent activity, pelareorep can also work in synergy with chemotherapy, immune checkpoint inhibitors (ICIs), CAR T-cell therapy, proteasome inhibitors, bispecific antibodies, and CDK4/6 and PARP inhibitors to enhance its antitumor potential and meaningfully extend patient remissions. Pelareorep specifically targets cancer cells and induces a cascade of inflammatory responses that activate the innate and adaptive immune system to destroy the tumor while sparing normal tissue. Pelareorep’s unique ability to introduce double-stranded RNA, a powerful immune stimulant, directly into cancer cells results in PD-L1 upregulation and cytokine and chemokine production, inducing enhanced infiltration and T-cell activation. Because pelareorep replicates only in tumor cells, it is well-tolerated by patients. Pelareorep Proposed Mechanism Of Action Oncolytics' Pipeline The cancer-fighting potential of pelareorep has generated partnerships with leading academic institutions and pharmaceutical industry collaborators. Given the validity of the mechanism of action and the efficacy observed thus far, the Company anticipates that its benefits will extend across multiple indications, including breast, gastrointestinal (GI), and hematologic malignancies. Discover Sources And More Here: ONCY Website. ONCY Presentation. ----- 5 Potential Catalysts Hit Our Radar For Monday - (Nasdaq: ONCY) 1.) An Average Analyst Target May Be Signaling That ONCY Is Undervalued From Its Current Chart Positioning. Take a look at this info found over at MarketBeat: From Friday's close, the average target of $8.50 that 4 analysts are projecting signal a potential upside of 650+%. From current chart levels, do these targets suggest (Nasdaq: ONCY) is underappreciated? 2.) A New Analyst Target Also Spells Triple-Digit Potential Upside For ONCY. In April, David Bautz of Zacks Small-Cap Research pegged a $6.00 target on ONCY. From its closing valuation on Friday, this target suggests ONCY may have a potential 450+% upside. 3.) Oncolytics Biotech® To Present Data At ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors. Oncolytics Biotech reported it has compelling translational data for pelareorep ahead of 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting, reinforcing its promise across gastrointestinal cancers. Findings from GOBLET and AWARE-1 trials show pelareorep activates both innate and adaptive immune responses, expands tumor-infiltrating lymphocytes, and promotes inflammatory signaling linked to tumor control. Notably, the therapy enhances existing tumor-reactive immune cells rather than introducing new antigens, suggesting a targeted and efficient mechanism. Leadership emphasized that aligning mechanistic insights with clinical outcomes strengthens confidence in development strategy, positioning pelareorep as a differentiated and potentially impactful immunotherapy for difficult-to-treat cancers. 4.) Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer. Oncolytics Biotech announced highly encouraging durability data in second-line RAS-mutant MSS metastatic colorectal cancer, demonstrating a 19.5-month median response duration—approximately three to four times longer than historical benchmarks. These results highlight pelareorep’s potential to deliver sustained, meaningful benefit in a patient population with limited treatment options. The company is actively engaging with the FDA to pursue an accelerated approval pathway, supported by ongoing studies. The data is viewed by the company's leadership as a strong validation of pelareorep’s clinical value, reinforcing its potential to become a transformative therapy in colorectal cancer and a significant driver of future growth. 5.) ONCY Closed Above 4 Key Technical Chart Levels On Friday. At 4:00PM EST Friday, ONCY came to a close above 4 key technical chart levels in its: 20-Day Simple Moving Average (SMA) 50-Day SMA 5-Day Exponential Moving Average (EMA) 13-Day EMA Should support strengthen at those levels, ONCY may find the building blocks to sustain a recent surge that has seen it climb from the $.77 level less than 2 weeks ago. ----- Officially underway: coverage has begun on Oncolytics Biotech Inc. (Nasdaq: ONCY). Be on the lookout for updates coming out soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 05/31/2026 and ending on 06/01/2026 to publicly disseminate information about (ONCY:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from Oncolytics Biotech Inc., the issuer of (ONCY:US). Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (ONCY:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/oncy-x06le/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice